Adams Street Partners is the famous VC, which was founded in 1972. The venture was found in North America in United States. The main office of represented VC is situated in the Chicago.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Enterprise Software, SaaS. Among the most popular portfolio startups of the fund, we may highlight Myogen, Proteus Digital Health, VillageMD. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
Considering the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Adams Street Partners is 100-500 millions dollars. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 7-12 deals per year. Comparing to the other companies, this Adams Street Partners performs on 2 percentage points more the average number of lead investments. The important activity for fund was in 2007. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2018.
The fund was created by George Spencer, T. Bondurant French. The overall number of key employees were 70.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Adams Street Partners, startups are often financed by Trinity Ventures, Granite Ventures, Vertex Ventures. The meaningful sponsors for the fund in investment in the same round are Latterell Venture Partners, Accel, Vista Ventures. In the next rounds fund is usually obtained by Vista Ventures, River Cities Capital Funds, Latterell Venture Partners.
|$220M||10 Aug 2021||Boston, Massachusetts, United States|
|$125M||29 Jun 2021||Vancouver, British Columbia, Canada|
|$120M||23 Jun 2021||Paris, Ile-de-France, France|
|$200M||15 Jun 2021||San Francisco, California, United States|
|$136M||27 May 2021||Austin, Texas, United States|
|$25M||18 May 2021||Palo Alto, California, United States|
|$100M||10 Mar 2021||Bloomington, Indiana, United States|
|$45M||24 Feb 2021||Madison, Wisconsin, United States|
|$45M||28 May 2020||Radnor Township, Pennsylvania, United States|
– Nomad Health, the leading digital marketplace for temporary healthcare jobs, announced the completion of $63m in new equity and debt financing.
– Adams Street Partners led, and all existing investors participated, including Icon Ventures, Polaris Partners, RRE Ventures, .406 Ventures, First Round Capital, and Silicon Valley Bank.
– With this financing, the business has raised over $100m since the company’s inception in 2015.
– The funding will be used to support Nomad Health’s explosive growth, allowing the company to double down on efforts to hire, invest in the technology platform, and grow its national footprint.
– As the demands on the healthcare system have reached historic levels during the COVID-19 pandemic, the need and urgency for temporary healthcare staffing solutions has substantially increased.
– Reify Health announced a $220m Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
– This latest funding, which brings the company’s valuation to $2.2bn, underscores Reify Health’s success in dramatically shortening clinical trial timelines.
– Reify Health has built a new foundation for how clinical trials are run through its business entities, StudyTeam and Care Access.
– StudyTeam delivers the best-in-class technology platform for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly and Company, and approximately 4,000 research sites across 65 countries.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.